Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 113
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/1/1988
1.
Phase II/III Study of IFN-beta-ser/IFN-gamma Followed by DDP/VP-16 in Patients with Inoperable non-Small Cell Lung Cancer (Summary Last Modified 04/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
WCCC-CO-8751
NCI-V87-0225
Last Modified:
12/6/2007
 
First Published:
9/24/2003
2.
Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
Under 30
NCI
COG-AHOD0121
NCT00070187, AHOD0121
Last Modified:
9/27/2007
 
First Published:
9/1/1998
3.
Phase III Randomized Study of Autologous Graft Versus Host Disease in Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Any age
NCI
JHOC-97080106
JHOC-9726, NCI-V98-1453, NCT00003414
Last Modified:
5/22/2008
 
First Published:
1/1/2001
4.
Phase III Randomized Study of High-Dose Cyclophosphamide, Thiotepa, and Carboplatin and Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Conjunction With Cyclosporine and Interferon Gamma Versus Interleukin-2 as Immunomodulation in Women With High-Risk Stage II or III Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 to physiologic 65
NCI
CPMC-IRB-7608
CPMC-CAMP-014, NCI-G00-1890, NCT00008203
5.
Phase III Comparison of Immuneron vs Depo-Provera in Patients with Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 75
BGSM-89285
NCI-V85-0243
6.
Phase III Randomized Trial of Immunotherapy with IFN-alpha vs IFN-gamma vs IFN-alpha/IFN-gamma in Patients with Advanced Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
BGSM-89186
NCI-V86-0108
Last Modified:
3/1/2001
7.
Phase III Randomized Evaluation of Dosage Schedule and Sequencing of VP-16/CACP Combination Chemotherapy as Induction Therapy and Randomized Study of Gamma IFN for Intensification of CR in Small Cell Lung Cancer (Summary Last Modified 03/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
NCCTG-862051
NCCTG-86-20-51
Last Modified:
5/9/2007
8.
Phase III Randomized Trial of Adjuvant Recombinant Human Interferon-Gamma vs No Adjuvant Therapy Following Complete Surgical Excision in Patients with Stage I/II Melanoma at High Risk for Recurrence
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 to physiologic 70
NCI
SWOG-8642
SWOG-8642
Last Modified:
2/20/2008
9.
Phase III Randomized Trial of Recombinant IFN-G and of 5-FU/CF as Adjuvant Therapy vs No Adjuvant Therapy in Patients with Resectable Adenocarcinoma of the Colon
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
NCCTG-874651
MAYO-874651, MDA-DM-89021, NCCTG-87-46-51
Last Modified:
6/1/1988
10.
Phase III Randomized Study of Adjuvant Treatment with IFN-A vs IFN-G vs No Adjuvant Therapy in Patients with Resected High-Risk Stage I/IIB Malignant Melanoma (Summary Last Modified 06/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
any age
EORTC-18871
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute